Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
How does TRELEGY Ellipta compare to other Single-inhaler Triple Therapies (SITTs)?
Until now it may have been difficult to assess how the benefits of different single-inhaler Triple Therapies (SITTs) compare in COPD. But a large new network meta-analysis has found superior lung function improvement and greater moderate/severe exacerbation reduction with TRELEGY Ellipta vs. other SITTs.*1,2 This new data may help support your treatment decisions for symptomatic patients with COPD at risk of exacerbation† despite ICS/LABA or LAMA/LABA maintenance treatment.
*Network meta-analysis of 23 RCTs, informed by 17 trials reporting moderate/severe exacerbation endpoints, 5 trials reporting trough FEV1 at 24 weeks and 15 trials reporting trough FEV1 at 12 weeks, in adult COPD patients eligible for triple therapy. The analysis included single- and multiple-inhaler triple therapies, ICS/LABA and LAMA/LABA, and tiotropium monotherapy. Analysis is limited by differences in study design and patient characteristics between trials.1,2
†With worsening of symptoms, or a history of an exacerbation, treated with antibiotics or oral corticosteroids, in the past 12 months.
This new network meta-analysis indicates that TRELEGY Ellipta could help improve lung function and reduce COPD exacerbation rates for your patients relative to other available SITTs.1,2
Superior lung function improvement with TRELEGY Ellipta vs. other single-inhaler Triple Therapies in a network meta-analysis*2
In a network meta-analysis of 23 RCTs, TRELEGY Ellipta demonstrated a superior 111 mL lung function improvement vs. Budesonide/Glycopyrronium/Formoterol (BUD/GLY/FOR):2
- Trough FEV1 with FF/UMEC/VI (92/55/22 mcg) vs. BUD/GLY/FOR (320/18/9.6 mcg); 95% CI: 79.8, 142.6; p<0.0001; analysis informed by 5 trials reporting FEV1 at 24 weeks
Greater moderate/severe exacerbation reduction with TRELEGY Ellipta vs. other single-inhaler Triple Therapies in a network meta-analysis*1
Network meta-analysis of 23 RCTs, informed by 17 trials reporting moderate/severe exacerbation endpoints, 5 trials reporting trough FEV1 at 24 weeks and 15 trials reporting trough FEV1 at 12 weeks, in adult COPD patients eligible for triple therapy. The analysis included single- and multiple-inhaler triple therapies, ICS/LABA and LAMA/LABA, and tiotropium monotherapy. Analysis is limited by differences in study design and patient characteristics between trials.1,2
Get started with Trelegy Ellipta
Footnotes
BD, twice daily; BUD, budesonide; CAT, COPD assessment test; FEV1, forced expiratory volume in one second; FF, fluticasone furoate; FOR, formoterol; HRQoL, health-related quality of life; ICS, inhaled corticosteroid; LABA, long- acting ß2-agonist; LAMA, long-acting muscarinic antagonist; LS, least squares; MCID, minimal clinically important difference; OD, once daily; UMEC, umeclidinium; VI, vilanterol
Safety information
TRELEGY Ellipta OD (fluticasone furoate/umeclidinium/vilanterol) is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA.3
TRELEGY Ellipta is generally well tolerated. Common adverse reactions include: headache, nasopharyngitis, influenza, upper respiratory tract infection, pneumonia, back pain, rhinitis, cough, pharyngitis and arthralgia.3
In common with other corticosteroid-containing medicines, there is an increased risk of pneumonia in patients with COPD receiving TRELEGY Ellipta.3
TRELEGY Ellipta should be used with caution in patients with unstable or life-threatening cardiovascular disease.3
References
- Ismalia A et al. ATS 2022. P649
- Ismalia A et al. ATS 2022. P478
- TRELEGY Ellipta SmPC, 2022. Available at www.medicines.ie. Accessed February 2023.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Trelegy is a registered trademark if the GlaxoSmithKline group of companies.
TRELEGY Ellipta was developed in collaboration with
Created: February 2023 PM-IE-FVU-WCNT-220021
